2023
Improving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches
Brooks R, Wegener M, Freeman B, Fowles C, Madden L, Tetrault J, Nichols L, Altice F, Villanueva M. Improving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches. Health Promotion Practice 2023, 24: 1018-1028. PMID: 37439759, DOI: 10.1177/15248399231169791.Peer-Reviewed Original ResearchMeSH KeywordsCoinfectionHepacivirusHepatitis CHIV InfectionsHumansOpiate AlkaloidsSubstance-Related DisordersConceptsHIV/HCV coinfectionSubstance use disorder programsHCV testingOpiate use disorderHCV coinfectionUse disordersNominal group techniqueSubstance use disorder treatment centersCascade of careRates of HIVDisorder treatment centersQuality improvement effortsRate of testingHCV acquisitionHCV cureImproving HIVSUD clinicsHepatitis CHIV testingPrior diagnosisSubsequent referralReferral ratesHIV epidemicHIVTreatment centers
2021
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
Domingo P, Mur I, Mateo G, Gutierrez M, Pomar V, de Benito N, Corbacho N, Herrera S, Millan L, Muñoz J, Malouf J, Molas M, Asensi V, Horcajada J, Estrada V, Gutierrez F, Torres F, Perez-Molina J, Fortun J, Villar L, Hohenthal U, Marttila H, Vuorinen T, Nordberg M, Valtonen M, Frigault M, Mansour M, Patel N, Fernandes A, Harvey L, Foulkes A, Healy B, Shah R, Bensaci A, Woolley A, Nikiforow S, Lin N, Sagar M, Shrager H, Huckins D, Axelrod M, Pincus M, Fleisher J, Lampa J, Nowak P, Vesterbacka J, Rasmuson J, Skorup P, Janols H, Niward K, Chatzidionysiou K, Asgeirsson H, Parke Å, Blennow O, Svensson A, Aleman S, Sönnerborg A, Henter J, Horne A, Al-Beidh F, Angus D, Annane D, Arabi Y, Beane A, Berry S, Bhimani Z, Bonten M, Bradbury C, Brunkhorst F, Buxton M, Cheng A, Cove M, De Jong M, Derde L, Estcourt L, Goossens H, Gordon A, Green C, Haniffa R, Ichihara N, Lamontagne F, Lawler P, Litton E, Marshall J, McArthur C, McAuley D, McGuinness S, McVerry B, Montgommery S, Mouncey P, Murthy S, Nichol A, Parke R, Parker J, Reyes F, Rowan K, Saito H, Santos M, Seymour C, Shankar-Hari M, Turgeon A, Turner A, van Bentum-Puijk W, van de Veerdonk F, Webb S, Zarychanski R, Baillie J, Beasley R, Cooper N, Fowler R, Galea J, Hills T, King A, Morpeth S, Netea M, Ogungbenro K, Pettila V, Tong S, Uyeki T, Youngstein T, Higgins A, Lorenzi E, Berry L, Salama C, Rosas I, Ruiz-Antorán B, Muñez Rubio E, Ramos Martínez A, Campos Esteban J, Avendaño Solá C, Pizov R, Sanz Sanz J, Abad-Santos F, Bautista-Hernández A, García-Fraile L, Barrios A, Gutiérrez Liarte Á, Alonso Pérez T, Rodríguez-García S, Mejía-Abril G, Prieto J, Leon R, VEIGA V, SCHEINBERG P, FARIAS D, PRATS J, CAVALCANTI A, MACHADO F, ROSA R, BERWANGER O, AZEVEDO L, LOPES R, DOURADO L, CASTRO C, ZAMPIERI F, AVEZUM A, LISBOA T, ROJAS S, COELHO J, LEITE R, CARVALHO J, ANDRADE L, SANDES A, PINTÃO M, SANTOS S, ALMEIDA T, COSTA A, GEBARA O, FREITAS F, PACHECO E, MACHADO D, MARTIN J, CONCEIÇÃO F, SIQUEIRA S, DAMIANI L, ISHIHARA L, SCHNEIDER D, DE SOUZA D, Hermine O, Mariette X, Tharaux P, Resche Rigon M, Porcher R, Ravaud P, Azoulay E, Cadranel J, Emmerich J, Fartoukh M, Guidet B, Humbert M, Lacombe K, Mahevas M, Pene F, Pourchet-Martinez V, Schlemmer F, Tibi A, Yazdanpanah Y, Dougados M, Bureau S, Horby P, Landray M, Baillie K, Buch M, Chappell L, Day J, Faust S, Haynes R, Jaki T, Jeffery K, Juszczak E, Lim W, Mafham M, Montgomery A, Mumford A, Thwaites G, Kamarulzaman A, Syed Omar S, Ponnampalavanar S, Raja Azwa R, Wong P, Kukreja A, Ong H, Sulaiman H, Basri S, Ng R, Megat Johari B, Rajasuriar R, Chong M, Neelamegam M, Syed Mansor S, Zulhaimi N, Lee C, Altice F, Price C, Malinis M, Hasan M, Wong C, Chidambaram S, Misnan N, Mohd Thabit A, Sim B, Bidin F, Mohd Abd Rahim M, Saravanamuttu S, Tuang W, Mohamed Gani Y, Thangavelu S, Tay K, Ibrahim N, Halid L, Tan K, Mukri M, Arip M, Koh H, Syed Badaruddin S, Raja Sureja L, Chun G, TORRE-CISNEROS J, MERCHANTE N, LEON R, CARCEL S, GARRIDO J, Galun E, Soriano A, Martínez J, Castán C, Paredes R, Dalmau D, Carbonell C, Espinosa G, Castro P, Muñóz J, Almuedo A, Prieto S, Pacheco I, Ratain M, Pisano J, Strek M, Adegunsoye A, Karrison T, Jozefien D, Karel F.A. V, Elisabeth D, Cedric B, Bastiaan M, Shankar-Hari M, Vale C, Godolphin P, Fisher D, Higgins J, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty J, Berry L, Broman N, Cavalcanti A, Colman R, De Buyser S, Derde L, Domingo P, Omar S, Fernandez-Cruz A, Feuth T, Garcia F, Garcia-Vicuna R, Gonzalez-Alvaro I, Gordon A, Haynes R, Hermine O, Horby P, Horick N, Kumar K, Lambrecht B, Landray M, Leal L, Lederer D, Lorenzi E, Mariette X, Merchante N, Misnan N, Mohan S, Nivens M, Oksi J, Perez-Molina J, Pizov R, Porcher R, Postma S, Rajasuriar R, Ramanan A, Ravaud P, Reid P, Rutgers A, Sancho-Lopez A, Seto T, Sivapalasingam S, Soin A, Staplin N, Stone J, Strohbehn G, Sunden-Cullberg J, Torre-Cisneros J, Tsai L, van Hoogstraten H, van Meerten T, Veiga V, Westerweel P, Murthy S, Diaz J, Marshall J, Sterne J. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA 2021, 326: 499-518. PMID: 34228774, PMCID: PMC8261689, DOI: 10.1001/jama.2021.11330.Peer-Reviewed Original ResearchConceptsIL-6 antagonistsUsual careCause mortalitySummary odds ratiosOdds ratioEligible trialsMechanical ventilationClinical trialsMortality riskSecondary infectionCOVID-19Primary outcome measureAbsolute mortality riskBias assessment toolRisk of biasStudy selection criteriaCochrane riskSecondary outcomesI2 statisticPlaceboOutcome measuresMAIN OUTCOMEPatientsAdditional trialsPrimary analysis
2018
Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era
Sacks‐Davis R, Doyle JS, Rauch A, Beguelin C, Pedrana AE, Matthews GV, Prins M, van der Valk M, Klein MB, Saeed S, Lacombe K, Chkhartishvili N, Altice FL, Hellard ME. Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era. Journal Of The International AIDS Society 2018, 21: e25051. PMID: 29633559, PMCID: PMC5978682, DOI: 10.1002/jia2.25051.Peer-Reviewed Original ResearchConceptsCo-infected populationHIV co-infected populationElimination initiativeHCV eliminationHIV/HCV co-infected populationCare dataHCV treatment uptakeSustained virological responseHalf of patientsDAA eraDAA treatmentHCV careSVR ratesVirological responseHCV infectionHCV treatmentHCV RNAImplementation science frameworkTreatment uptakeHigh-income countriesHIVIntervention characteristicsTreatment availabilityDiagnosis rateElimination program
2017
Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes
Mazhnaya A, Meteliuk A, Barnard T, Zelenev A, Filippovych S, Altice FL. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes. International Journal Of Drug Policy 2017, 47: 187-195. PMID: 28811159, PMCID: PMC5918282, DOI: 10.1016/j.drugpo.2017.07.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsCoinfectionFemaleGenotypeHealth ServicesHepacivirusHepatitis CHIV InfectionsHumansInterferon-alphaMalePolyethylene GlycolsProgram DevelopmentProgram EvaluationRecombinant ProteinsRibavirinRisk FactorsSex FactorsSofosbuvirSubstance Abuse, IntravenousSustained Virologic ResponseTreatment OutcomeUkraineYoung AdultConceptsSustained virologic responseHCV treatmentRisk groupsSVR ratesMedical recordsDirect acting antiviral medicationsComparable SVR ratesHCV genotype 3HCV prevalence estimatesHCV treatment servicesActing antiviral (DAA) medicationsCombination of sofosbuvirHigh-risk groupPatient-level outcomesProportion of participantsCommunity-based settingsDAA treatmentVirologic responseAntiviral medicationsHIV characteristicsHCV genotypesIndependent correlatesSVR dataFemale sexGenotype 3
2016
Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees
Dolan K, Wirtz AL, Moazen B, Ndeffo-mbah M, Galvani A, Kinner SA, Courtney R, McKee M, Amon JJ, Maher L, Hellard M, Beyrer C, Altice FL. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. The Lancet 2016, 388: 1089-1102. PMID: 27427453, DOI: 10.1016/s0140-6736(16)30466-4.Peer-Reviewed Original ResearchConceptsHepatitis B virusHepatitis C virusViral hepatitisChronic hepatitis B virusBurden of HIVOpioid agonist therapyPrevalence of HIVTreatment of HIVIncarceration of peopleComprehensive literature searchAgonist therapyActive tuberculosisHIV transmissionC virusB virusGlobal burdenPrevention interventionsGeneral populationGlobal epidemiologyHIVDrug useTuberculosisLiterature searchLarge-scale outbreaksHepatitisIntersecting epidemics of HIV, HCV, and syphilis among soon-to-be released prisoners in Kyrgyzstan: Implications for prevention and treatment
Azbel L, Polonsky M, Wegman M, Shumskaya N, Kurmanalieva A, Asanov A, Wickersham JA, Dvoriak S, Altice FL. Intersecting epidemics of HIV, HCV, and syphilis among soon-to-be released prisoners in Kyrgyzstan: Implications for prevention and treatment. International Journal Of Drug Policy 2016, 37: 9-20. PMID: 27455177, PMCID: PMC5124506, DOI: 10.1016/j.drugpo.2016.06.007.Peer-Reviewed Original ResearchConceptsDrug injectionHIV infectionLifetime drug injectionPrison drug injectionHIV care continuumAntiretroviral therapy coverageConfidence intervalsMean numberEpidemic of HIVHealth assessment surveyUndiagnosed syphilisSyphilis infectionConsented participantsHIV incidenceHIV transmissionIndependent correlatesWeighted prevalenceEvidence-based responsesHIV epidemicCare continuumDuration of imprisonmentHIV preventionHealth SurveyAIDS mortalityHIV
2015
Challenges in managing HIV in people who use drugs
Kamarulzaman A, Altice FL. Challenges in managing HIV in people who use drugs. Current Opinion In Infectious Diseases 2015, 28: 10-16. PMID: 25490106, PMCID: PMC4409950, DOI: 10.1097/qco.0000000000000125.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsCoinfectionComorbidityContinuity of Patient CareHealth Services AccessibilityHepatitis CHIV InfectionsHumansMedication AdherenceMental DisordersNeedle-Exchange ProgramsOpiate Substitution TreatmentSocial ClassSubstance Abuse, IntravenousSubstance-Related DisordersTuberculosisConceptsOpioid substitution therapyHepatitis C virusHIV continuumTreatment outcomesImproved ART adherenceInterferon-based regimesTB treatment outcomesHIV treatment outcomesBetter treatment retentionEvidence-based preventionHIV treatment accessHIV-HCVNoninfectious comorbiditiesOST servicesCare retentionART adherenceHIV managementAntiretroviral adherencePsychiatric comorbiditySubstitution therapyHIV treatmentNew diagnostic technologiesC virusClinical managementEarly diagnosis
2013
Prevalence of tuberculosis symptoms and latent tuberculous infection among prisoners in northeastern Malaysia
Margolis B, Al-Darraji HA, Wickersham JA, Kamarulzaman A, Altice FL. Prevalence of tuberculosis symptoms and latent tuberculous infection among prisoners in northeastern Malaysia. The International Journal Of Tuberculosis And Lung Disease 2013, 17: 1538-1544. PMID: 24200265, PMCID: PMC3913085, DOI: 10.5588/ijtld.13.0193.Peer-Reviewed Original ResearchConceptsLatent tuberculous infectionTuberculin skin testTB symptomsTuberculous infectionTwo-step tuberculin skin testPrevious incarcerationHuman immunodeficiency virus (HIV) infectionLower body mass indexReactive tuberculin skin testImmunodeficiency virus infectionBody mass indexRoutine screening procedureCross-sectional surveyCD4 statusRoutine tuberculosisTST reactivityTuberculosis symptomsActive tuberculosisLTBI prevalenceOnly significant correlateMass indexNortheastern MalaysiaSkin testVirus infectionHIVLatent Tuberculosis Infection: Screening and Treatment in an Urban Setting
Morano JP, Walton MR, Zelenev A, Bruce RD, Altice FL. Latent Tuberculosis Infection: Screening and Treatment in an Urban Setting. Journal Of Community Health 2013, 38: 941-950. PMID: 23728822, PMCID: PMC3781590, DOI: 10.1007/s10900-013-9704-y.Peer-Reviewed Original ResearchConceptsIsoniazid preventative therapyLatent tuberculosis infectionTuberculin skin testSelf-administered therapyActive tuberculosisRecent incarcerationNew latent tuberculosis infectionsPositive tuberculin skin testMobile outreach clinicHigh tuberculosis prevalenceMultivariate logistic regressionInner-city populationDOT participantsLTBI treatmentObserved therapyTuberculosis infectionPreventative therapySkin testChest radiographsTuberculosis prevalenceOutreach clinicsCXR screeningHealthcare clinicsYounger ageSimilar outcomesThe Burgeoning HIV/HCV Syndemic in the Urban Northeast: HCV, HIV, and HIV/HCV Coinfection in an Urban Setting
Morano JP, Gibson BA, Altice FL. The Burgeoning HIV/HCV Syndemic in the Urban Northeast: HCV, HIV, and HIV/HCV Coinfection in an Urban Setting. PLOS ONE 2013, 8: e64321. PMID: 23691197, PMCID: PMC3653872, DOI: 10.1371/journal.pone.0064321.Peer-Reviewed Original ResearchConceptsHIV/HCV coinfectionHCV coinfectionHIV monoinfectionTransmission risk behaviorsCross-sectional studyMobile medical clinicViral infection statusCrack cocaine useHCV monoinfectionHCV infectionIndependent correlatesCoinfection statusLifetime HIVClinical careHCVHIVMonoinfectionElectronic databasesDisease preventionCocaine useMedical clinicsRisk behaviorsGallery useInfection statusCoinfection
2012
Survival from XDR-TB Is Associated with Modifiable Clinical Characteristics in Rural South Africa
Shenoi SV, Brooks RP, Barbour R, Altice FL, Zelterman D, Moll AP, Master I, van der Merwe TL, Friedland GH. Survival from XDR-TB Is Associated with Modifiable Clinical Characteristics in Rural South Africa. PLOS ONE 2012, 7: e31786. PMID: 22412840, PMCID: PMC3295798, DOI: 10.1371/journal.pone.0031786.Peer-Reviewed Original ResearchConceptsXDR-TB patientsDrug-resistant tuberculosisRetrospective case-control studyXDR-TB casesCommunity-based hospitalCase-control studyGlobal public healthHIV coinfectionMicrobiological correlatesModifiable factorsAvailable interventionsRural South AfricaControl studyPatientsTuberculosisPublic healthSurvivorsSurvivalDaysHospitalMortality